The short-term and long-term adverse ocular effects of fesoterodine fumarate

Abstract

Aim: To evaluate the short-term and long-term effects of fesoterodine fumarate treatment which is used for overactive bladder (OAB) on pupil diameter (PD), intraocular pressure (IOP) and accommodation amplitude (AA).

Method: Ophthalmic examination was performed before and after receiving medication (on the 30th and 90th day) on 120 eyes of 120 women whom were planned to begin anticholinergic treatment (fesoterodine fumarate, 4 mg/day, peroral) for OAB, prospectively. The changes in PD, IOP and AA were analyzed statistically.

Results: The mean age of 120 women was 52.06 ± 9.39 years (30–70 years). The mean PD, IOP and AA values were 4.12 ± 0.61 mm (3.00–5.70 mm), 15.58 ± 1.74 mmHg (11–20 mmHg) 2.28 ± 1.26 Diopter (D) (0.50–5.50 D) at baseline; 4.68 ± 0.65 mm (3.20–5.80 mm), 16.11 ± 1.72 mmHg (11–20 mmHg), 1.68 ± 1.04 D (0.25–4.50 D) at 30th day; and 4.28 ± 0.58 mm (3.10–5.70 mm), 16.09 ± 1.96 mmHg (11–19 mmHg), 2.18 ± 1.19 D (0.50–5.00 D) at 90th day, respectively. Although increases in PD values and decreases in AA values were statistically significant (p < 0.001 for each), the changes in IOP values were not as such (p = 0.642). Visual complaint was not observed in any patient.

Discussion: The newest anticholinergic medication in women with OAB increased the PD and decreased the AA statistically significantly. Clinically, it seems to be well-tolerated by the patient.

• Accommodation amplitude
• fesoterodine fumarate
• intraocular pressure
• overactive bladder
• pupil diameter

Acknowledgement

The authors would like to thank Anıl Barak Dolgun who performed the statistical analysis of this article.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.